Arnon P Kater

60PUBLICATIONS
271CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyMedical mycologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (60)

|Oct 02, 2026
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.

|Sep 18, 2026
A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.

|Sep 04, 2026
Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.

|Aug 27, 2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

|Aug 24, 2026
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

|Jun 25, 2026
Necroptotic cell death and immunomodulator release induced by T-cell engaging anti-lymphoma therapies.

Pageof 10

Frequent Collaborators

14 joint publications

Carsten Utoft Niemann

13 joint publications

Mark-David Levin

11 joint publications

Eric Eldering

10 joint publications

John F Seymour